Skip to main content
. 2022 Feb 25;27(5):1560. doi: 10.3390/molecules27051560

Figure 2.

Figure 2

Effects of 1-iodohexadecane on immunoglobulin E-antigen complex-induced histamine and β-hexosaminidase release from RBL-2H3 cells. (a,b) Histamine and β-hexosaminidase releases from RBL-2H3 mast cells. After treatment for 48 h in the presence or absence of 1-iodohexadecane (1-Iodo; 25–100 μg/mL), cells were incubated with anti-dinitrophenyl-immunoglobulin E (anti-DNP-IgE; 200 ng/mL) for 10 h and then stimulated with 2,4-dinitrophenyl labeled-BSA (DNP-BSA: 10 ng/mL) for 1 h. Culture media were collected and centrifuged, and the levels of histamine (a; n = 3) and β-hexosaminidase (b; n = 3) in the supernatant (conditioned media) were measured using an enzyme immunoassay. The response in cells treated with anti-DNP-IgE alone was considered 100%. The results are represented as means ± SEMs. * p < 0.05 vs. DNP-BSA stimulated cells in the presence of anti-DNP-IgE alone. (c) Cell viability in RBL-2H3 cells exposed to 1-Iodo. Cells were treated with 1-Iodo (0.1–100 µg/mL) for 48 h. Cell viabilities were measured using an EZ-CyTox kit. The response levels are expressed as percentages of levels in untreated cells (n = 5). Results are expressed as means ± SEMs. * p < 0.05 vs. untreated cells.